Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
Nirmal Shaji George, Doctor of Pharmacy – PharmD at Nazareth College of Pharmacy, Othera, Tiruvalla, shared a post on LinkedIn:
“How do you manage thrombosis risk when a patient’s platelet count is dangerously low?
As part of my 4th-year Pharm.D clinical training, I recently worked on a case involving antiphospholipid syndrome (APS) complicated by severe thrombocytopenia – a challenging intersection of thrombosis and bleeding risk.
APS is an autoimmune, hypercoagulable disorder associated with antiphospholipid antibodies such as lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I antibodies.
While thrombosis and pregnancy morbidity form the major clinical criteria, thrombocytopenia is a recognized non-criteria manifestation of APS.
What made this case particularly valuable was the therapeutic dilemma: a patient with a strong thrombotic risk, but also an extremely low platelet count.
Anticoagulation therefore cannot be viewed simply as ‘preventing clots’ – the timing, intensity, bleeding risk, platelet recovery, and overall clinical context all matter.
From a clinical pharmacy perspective, the case highlighted the importance of:
- Reviewing anticoagulation strategies according to the patient’s APS risk profile.
- Identifying drug–drug interactions and therapy-related risks.
- Monitoring platelet counts, bleeding, and thrombotic events.
- Providing clear patient counselling regarding adherence and warning signs.
Clinical pearl: APS can present with both thrombotic complications and thrombocytopenia, making individualized pharmacotherapy essential.
This case reinforced for me that clinical pharmacy is not just about knowing the drug – it is about understanding the disease, the patient, and the balance between competing risks.
I’d be glad to connect with others interested in clinical pharmacy, anticoagulation, and Pharm.D practice.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series